Trial reportThe Journal of infectious diseases2010
Kinetics of serum cytokines after primary or repeat vaccination with the smallpox vaccine.
Trial report in The Journal of infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00325975 (Immune Responses to Vaccinia Virus Vaccination), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immune Responses to Vaccinia Virus Vaccination
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Can the current monkeypox affect the heart? A systematic review of case series and case report.BMC cardiovascular disorders · 2023Pooled it
- mRNA vaccination using peptide nanoparticles triggers a strong immune response against endogenous GPC2 in a murine neuroblastoma model.Molecular therapy. Oncology · 2026Article
- Observational
- Cardiac Adverse Events Following COVID-19 Vaccination in Patients With Prior Vaccine-Associated Myocarditis.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2023Article
- Atypical Clinical Presentation of Monkeypox Complicated by Myopericarditis.Open forum infectious diseases · 2022Article
- The characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic.Cephalalgia : an international journal of headache · 2022Article
- Case report: From monkeypox pharyngitis to myopericarditis and atypical skin lesions.Frontiers in cardiovascular medicine · 2022Article
- Defending against smallpox: a focus on vaccines.Expert review of vaccines · 2016Review
- Impaired innate, humoral, and cellular immunity despite a take in smallpox vaccine recipients.Vaccine · 2016Article
- Observational
- Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma.Annals of surgical oncology · 2014Article
- Protective properties of vaccinia virus-based vaccines: skin scarification promotes a nonspecific immune response that protects against orthopoxvirus disease.Journal of virology · 2014Article
- Cytokine production associated with smallpox vaccine responses.Immunotherapy · 2014Review
- Correlations between vaccinia-specific immune responses within a cohort of armed forces members.Viral immunology · 2011Article
- Smallpox vaccines: targets of protective immunity.Immunological reviews · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe smallpox vaccine is associated with more serious adverse events than any other live attenuated vaccine in use today. Although studies have examined serum cytokine levels in primary vaccine recipients at 1 and 3-5 weeks after vaccination with the smallpox vaccine, serial measurements have not been performed, and studies in revaccinated subjects have not been conducted.
methodsWe analyzed cytokine responses in both primary vaccine recipients and revaccinated subjects every other day for 2 weeks after vaccination.
resultsPrimary vaccine recipients had maximal levels of granulocyte-colony-stimulating factor on days 6-7 after vaccination; peak levels of tumor necrosis factor (TNF)-alpha, soluble TNF receptor 1, interferon (IFN)-gamma, IFN-inducible protein-10 (IP-10), interleukin (IL)-6, and tissue inhibitor of metalloproteinases-1 on days 8-9 after vaccination; peak levels of soluble TNF receptor 2 and monokine induced by IFN-gamma (MIG) on days 10-11 after vaccination; and peak levels of granulocyte-macrophage-colony-stimulating factor on days 12-13 after vaccination. Primary vaccine recipients were significantly more likely to have higher peak levels of IFN-gamma, IP-10, and MIG after vaccination than were revaccinated subjects. Primary vaccine recipients were significantly more likely to have fatigue, lymphadenopathy, and headache, as well as a longer duration of these symptoms and more hours missed from work, compared with revaccinated subjects.
conclusionsThe increased frequency and duration of symptoms observed in primary vaccine recipients, compared with revaccinated subjects, paralleled the increases in serum cytokine levels in these individuals.
trial registrationClinicaltrials.gov identifier NCT00325975.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.